Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
Dyslipidemia makes a substantial contribution to the mortality as one of the leading pathogenetic factors for cardiovascular diseases. The nature and degree of the effect on the blood lipid spectrum may vary in the lipid-lowering drugs from different groups. Recently, a new class of PCSK9 inhibitors...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2021-01-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/5961 |
| _version_ | 1797841470541004800 |
|---|---|
| author | A. A. Shikaleva M. L. Maximov N. M. Kiseleva |
| author_facet | A. A. Shikaleva M. L. Maximov N. M. Kiseleva |
| author_sort | A. A. Shikaleva |
| collection | DOAJ |
| description | Dyslipidemia makes a substantial contribution to the mortality as one of the leading pathogenetic factors for cardiovascular diseases. The nature and degree of the effect on the blood lipid spectrum may vary in the lipid-lowering drugs from different groups. Recently, a new class of PCSK9 inhibitors has been developed, which activity is associated with a protein involved in the low-density lipoprotein receptor control. In clinical practice, this group is represented by monoclonal antibody drugs evolocumab and alirocumab. The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are promising drugs to be used in the combination lipid-lowering therapy, which, given the results of clinical trials, can be recommended at this point on a third-priority basis after statins and ezetimibe. However, it is vital to indicate that these drugs have a sufficient safety profile, which makes it possible to prescribe these drugs in a triple combination adding it to the two first-line drugs regimen which patients had been given before. It is obvious that further study of PCSK9 will expand the range of their use for the treatment of familial hypercholesterolemia up to indications in cases where statins are limited and a more pronounced lipid-lowering effect is required to achieve target cholesterol levels. |
| first_indexed | 2024-04-09T16:32:37Z |
| format | Article |
| id | doaj.art-01d4776d56bb49a481baa5d853a4b438 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:32:37Z |
| publishDate | 2021-01-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-01d4776d56bb49a481baa5d853a4b4382023-04-23T06:57:02ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902021-01-01021121810.21518/2079-701X-2020-21-12-185425Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemiaA. A. Shikaleva0M. L. Maximov1N. M. Kiseleva2Kazan State Medical UniversityKazan State Medical Academy; Pirogov Russian National Research Medical UniversityPirogov Russian National Research Medical UniversityDyslipidemia makes a substantial contribution to the mortality as one of the leading pathogenetic factors for cardiovascular diseases. The nature and degree of the effect on the blood lipid spectrum may vary in the lipid-lowering drugs from different groups. Recently, a new class of PCSK9 inhibitors has been developed, which activity is associated with a protein involved in the low-density lipoprotein receptor control. In clinical practice, this group is represented by monoclonal antibody drugs evolocumab and alirocumab. The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are promising drugs to be used in the combination lipid-lowering therapy, which, given the results of clinical trials, can be recommended at this point on a third-priority basis after statins and ezetimibe. However, it is vital to indicate that these drugs have a sufficient safety profile, which makes it possible to prescribe these drugs in a triple combination adding it to the two first-line drugs regimen which patients had been given before. It is obvious that further study of PCSK9 will expand the range of their use for the treatment of familial hypercholesterolemia up to indications in cases where statins are limited and a more pronounced lipid-lowering effect is required to achieve target cholesterol levels.https://www.med-sovet.pro/jour/article/view/5961proprotein convertase subtilisin/kexin type 9pcsk9ldl receptordyslipidemiastatinscholesterolhyperlipidemia |
| spellingShingle | A. A. Shikaleva M. L. Maximov N. M. Kiseleva Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia Медицинский совет proprotein convertase subtilisin/kexin type 9 pcsk9 ldl receptor dyslipidemia statins cholesterol hyperlipidemia |
| title | Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia |
| title_full | Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia |
| title_fullStr | Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia |
| title_full_unstemmed | Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia |
| title_short | Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia |
| title_sort | proprotein convertase subtilisin kexin type 9 pcsk9 inhibitors in the treatment of dyslipidemia |
| topic | proprotein convertase subtilisin/kexin type 9 pcsk9 ldl receptor dyslipidemia statins cholesterol hyperlipidemia |
| url | https://www.med-sovet.pro/jour/article/view/5961 |
| work_keys_str_mv | AT aashikaleva proproteinconvertasesubtilisinkexintype9pcsk9inhibitorsinthetreatmentofdyslipidemia AT mlmaximov proproteinconvertasesubtilisinkexintype9pcsk9inhibitorsinthetreatmentofdyslipidemia AT nmkiseleva proproteinconvertasesubtilisinkexintype9pcsk9inhibitorsinthetreatmentofdyslipidemia |